Retinologische Notfälle

Einleitung

Bei verschiedenen Netzhauterkrankungen bestimmt das schnelle und adäquate Handeln des Erstuntersuchers die Prognose erheblich. Ein möglichst reibungsloses und gutes Zusammenspiel zwischen den Beteiligten der Behandlungskette ist erforderlich. Das korrekte und zeitgerechte Management verschiedener typischer retinologischer Notfallsituationen soll daher Thema dieses Fortbildungsartikels sein. Dabei haben wir uns auf 2 häufige und eine seltenere, aber umso dringlichere retinale Erkrankung fokussiert: die akute retinale Nekrose, die rhegmatogene Ablatio und die retinalen Gefäßverschlüsse. Antworten auf die folgenden Fragen sollen dem Leser vermittelt werden:

Woran erkenne ich eine akute retinale Nekrose? Wann ist eine Ablatio ein Notfall? Welcher Gefäßverschluss ist dringlich?

Literatur

• 1 Urayama A, Yamada N, Sasaki T. Unilateral acute uveitis with retinal periarteritis and detachment.  Rinsho Ganka. 1971;  25 607-619
• 2 Young N J, Bird A C. Bilateral acute retinal necrosis.  Br J Ophthalmol. 1978;  62 581-590
• 3 Culbertson W W, Blumenkranz M S, Haines H et al. The acute retinal necrosis syndrome. Part 2: histopathology and etiology.  Ophthalmology. 1982;  89 1317-1325
• 4 Culbertson W W, Blumenkranz M S, Pepose J S et al. Varicella zoster virus is a cause of the acute retinal necrosis syndrome.  Ophthalmology. 1986;  93 559-569
• 5 Lewis M L, Culbertson W W, Post J D et al. Herpes simplex virus type 1: a cause of the acute retinal necrosis syndrome.  Ophthalmology. 1989;  96 875-878
• 6 Lau C H, Missotten T, Salzmann J et al. Acute retinal necrosis. Features, management, and outcomes.  Ophthalmology. 2007;  114 756-762
• 7 Hillenkamp J, Nölle B, Bruns C et al. Acute retinal necrosis: clinical features, early vitrectomy, and outcomes.  Ophthalmology. DOI: 10.1016/j.ophtha.2009.03.029
• 8 Chodosh J, Gan Y J, Sixbey J W. Detection of Epstein-Barr virus genome in ocular tissue.  Ophthalmology. 1996;  103 687-690
• 9 Holland G N. Executive Committee of the American Uveitis Society . Standard diagnostic criteria for the acute retinal necrosis syndrome.  Am J Ophthalmol. 1994;  117 663-667
• 10 Matsuo T, Nakayama T, Koyama T et al. A proposed mild type of acute retinal necrosis.  Am J Ophthalmol. 1988;  105 579-583
• 11 Matsuo T, Morimoto K, Matsuo N. Factors associated with poor visual outcome in acute retinal necrosis.  Br J Ophthalmol. 1991;  75 450-454
• 12 Holland G N, Cornell P J, Park M S et al. An association between acute retinal necrosis syndrome and HLA-DQw7 and phenotype Bw62, DR4.  Am J Ophthalmol. 1989;  108 370-374
• 13 Matsuo T, Matsuo N. HLA-DR9 associated with the severity of acute retinal necrosis syndrome.  Ophthalmologica. 1991;  203 133-137
• 14 Labetoulle M, Kucera P, Ugolini G et al. Neuronal pathways for the propagation of herpes simplex virus type 1 from one retina to the other in a murine model.  J Gen Virol. 2000;  81 1201-1210
• 15 Muthiah M N, Michaelides M, Child C S et al. Acute retinal necrosis: a national population-based study to assess the incidence, methods of diagnosis, treatment strategies and outcomes in the UK.  Br J Ophthalmol. 2007;  91 1452-1455
• 16 Luu K K, Scott I U, Chaudhry N A et al. Intravitreal antiviral injections as adjunctive therapy in the management of immunocompetent patients with necrotizing herpetic retinopathy.  Am J Ophthalmol. 2000;  129 811-813
• 17 Scott I U, Luu K M, Davis J L. Intravitreal antivirals in the management of patients with acquired immunodeficiency syndrome with progressive outer retinal necrosis.  Arch Ophthalmol. 2002;  120 1219-1222
• 18 Emerson G G, Smith J R, Wilson D J et al. Primary treatment of acute retinal necrosis with oral antiviral therapy.  Ophthalmology. 2006;  113 2259-2261
• 19 Aizman A, Johnson M W, Elner S G. Treatment of acute retinal necrosis syndrome with oral antiviral medications.  Ophthalmology. 2007;  114 3-12
• 20 Ando F, Kato M, Goto S et al. Platelet function in bilateral acute retinal necrosis.  Am J Ophthalmol. 1983;  96 27-32
• 21 Han D P, Lewis H, Williams G A et al. Laser photocoagulation in the acute retinal necrosis syndrome.  Arch Ophthalmol. 1987;  105 1051-1054
• 22 Sternberg Jr. P, Han D P, Yeo J H et al. Photocoagulation to prevent retinal detachment in acute retinal necrosis.  Ophthalmology. 1988;  95 1389-1393
• 23 Crapotta J A, Freeman W R, Feldman R M et al. Visual outcome in acute retinal necrosis.  Retina. 1993;  13 208-213
• 24 Hudde T, Althaus C, Sundmacher R. Acute retinal necrosis syndrome: argon laser coagulation for prevention of rhegmatogenic retinal detachment (in German).  Ophthalmologe. 1998;  95 473-477
• 25 McDonald H R, Lewis H, Kreiger A E et al. Surgical management of retinal detachment associated with the acute retinal necrosis syndrome.  Br J Ophthalmol. 1991;  75 455-458
• 26 Park J J, Pavesio C. Prophylactic laser photocoagulation for acute retinal necrosis. Does it raise more questions than answers?.  Br J Ophthalmol. 2008;  92 2
• 27 Phan D D, Chin-Hong P, Lin E T et al. Intra- and interindividual variabilities of valaciclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor.  Antimicrob Agents Chemother. 2003;  47 2351-2353
• 28 Norton E W D. Retinal detachment in aphakia.  Trans Am Ophthalmol Soc. 1963;  61 770-789
• 29 Lincoff H. Guilty until proven innocent.  Arch Ophthalmol. 1967;  78 271
• 30 Burton T C. Recovery of visual acuity after retinal detachment involving the macula.  Trans Am Ophthalmol Soc. 1982;  80 475-497
• 31 Kreissig I, Lincoff H. Die unaufschiebbare Ablatiooperation.  Klin Mbl Augenheilkd. 1974;  165 315-318
• 32 Kreissig I. Weitere klinische Erfahrungen über die unaufschiebbare Ablatio-Operation.  Klin Mbl Augenheilkd. 1977;  171 530-538
• 33 Kreissig I. Prognosis of return of macular function after retinal reattachment.  Mod Probl Ophthalmol. 1977;  18 415
• 34 Gundry M F, Davies E W G. Recovery of visual acuity after retinal detachment surgery.  Am J Ophthalmol. 1974;  77 310
• 35 Frimpong-Ansah K, Kirkby G R. Arrangements for the management of urgent retinal detachments in the United Kingdom and Eire in the year 2000: Results of a survey.  Eye. 2002;  16 754-760
• 36 Hartz A J, Burton T C, Gottlieb M A et al. Outcome and cost analysis of scheduled versus emergency scleral buckling surgery.  Ophthalmology. 1992;  99 1358-1363
• 37 Cohen S M. Natural history of asymptomatic clinical retinal detachments.  Am J Ophthalmol. 2005;  139 777-779
• 38 Davis M D. The natural history of retinal breaks without detachment.  Arch Ophthalmol. 1974;  92 183-194
• 39 Byer N E. Subclinical retinal detachment resulting from asymptomatic retinal breaks: prognosis for progression and regression.  Ophthalmology. 2001;  108 1499-1503
• 40 Ross W H, Kozy D W. Visual recovery in macula-off rhegmatogenous retinal detachments.  Ophthalmology. 1998;  105 2149-2153
• 41 Ross W H. Visual recovery after macula-off retinal detachment.  Eye. 2002;  14 440-446
• 42 La Cour M. Persönliche Mitteilung. 
• 43 Mowatt L, Shun-Shin G A, Arora S et al. Macula off retinal detachments. How long can we wait before it is too late?.  Eur J Ophthalmol. 2005;  15 109-117
• 44 Winkler J, Hoerauf H. The retinal organ culture – a model system for the examination of the early cytoskeletal reaction pattern after retinal detachment.  Klin Mbl Augenheilkd. 2008;  225 269-275
• 45 Ross W, Lavina A, Russell M et al. The correlation between height of macular detachment and visual outcome in macula-off retinal detachments of < 7 days' duration.  Ophthalmology. 2005;  112 1213-1217
• 46 Tani P, Robertson D M, Langwothy A. Rhegmatogenous retinal detachment without macular involvement treated with scleral buckling.  Am J Ophthalmol. 1980;  90 503-508
• 47 Davidorf F H, Havener W H, Lang J R. Macular vision following retinal detachment surgery.  Ophthalmol Surg. 1975;  6 74
• 48 Machemer R. Experimental retinal detachment in the owl monkey. Histology of retina and pigment epithelium.  Am J Ophthalmol. 1968;  66 396
• 49 Hagimura N, Iida T, Suto K et al. Persistent foveal retinal detachment after successful rhegmatogenous retinal detachment surgery.  Am J Ophthalmol. 2002;  133 516-520
• 50 Hassan T S, Sarrafizadeh R, Ruby A J et al. The effect of duration of macular detachment on results after the scleral buckle repair of primary, macula-off retinal detachments.  Ophthalmology. 2002;  109 146-152
• 51 Kusaka S, Toshino A, Ohashi Y et al. Long-term visual recovery after scleral buckling for macular-off retinal detachments.  Jpn J Ophthalmol. 1998;  42 218-222
• 52 Feltgen N, Schmidt D, Hansen L. Arterielle retinale Verschlüsse.  Ophthalmologe. 2003;  100 651-665
• 53 Hayreh S S, Zimmerman M B. Central retinal artery occlusion: visual outcome.  Am J Ophthalmol. 2005;  140 376-391
• 54 Sharma S, Naqvi A, Sharma S M et al. Transthoracic echocardiographic findings in patients with acute central retinal artery obstruction. A retrospective review. Retinal Emboli of Cardiac Origin Group.  Arch Ophthalmol. 1996;  114 1189-1192
• 55 Kuhli-Hattenbach C, Scharrer I, Lüchtenberg M et al. Selective thrombophilia screening of patients with nonarteritic anterior ischemic optic neuropathy.  Graefes Arch Clin Exp Ophthalmol. 2009;  247 485-490
• 56 Nelson M E, Talbot J F, Preston F E. Recurrent multiple-branch retinal arteriolar occlusions in a patient with protein C deficiency.  Graefes Arch Clin Exp Ophthalmol. 1989;  227 443-447
• 57 Mueller A J, Neubauer A S, Schaller U et al. Evaluation of minimally invasive therapies and rationale for a prospective randomized trial to evaluate selective intra-arterial lysis for clinically complete central retinal artery occlusion.  Arch Ophthalmol. 2003;  121 1377-1381
• 58 The GUSTO Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.  N Engl J Med. 1993;  329 673-682
• 59 The GUSTO angiographic investigators . The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.  N Engl J Med. 1993;  329 1615-1622
• 60 Konstantinides S, Geibel A, Heusel G et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism.  N Engl J Med. 2002;  347 1143-1150
• 61 Brott T G, Haley Jr. E C, Levy D E. Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 minutes.  Stroke. 1992;  23 632-640
• 62 Haley Jr. E C, Levy D E, Brott T G. Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset.  Stroke. 1992;  23 641-645
• 63 Kolbel T, Lindh M, Holst J et al. Extensive acute deep vein thrombosis of the iliocaval segment: midterm results of thrombolysis and stent placement.  J Vasc Interv Radiol. 2007;  18 243-250
• 64 Ouriel K, Veith F J, Sasahara A A. Comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators.  N Engl J Med. 1998;  338 1105-1111
• 65 Bertram B, Wolf S, Fisches H et al. Lysebehandlung bei retinalen Arterienverschlüssen mit Plasminogen-Aktivator.  Klin Mbl Augenheilk. 1991;  198 295-300
• 66 Feltgen N, Neubauer A, Jurklies B et al. Multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) for the treatment of central retinal artery occlusion: design issues and implications. EAGLE Study report no.1.  Graefes Arch Clin Exp Ophthalmol. 2006;  244 950-956
• 67 Hattenbach L O, Kuhli-Hattenbach C, Scharrer I et al. Intravenous thrombolysis with low-dose recombinant tissue plasminogen activator in central retinal artery occlusion.  Am J Ophthalmol. 2008;  146 700-706
• 68 Biousse V. Thrombolysis for acute central retinal artery occlusion: is it time?.  Am J Ophthalmol. 2008;  146 631-634
• 69 Hayreh S S, Zimmermann M B, Kimura A et al. Central retinal artery occlusion. Retinal survival time.  Exp Eye Res. 2004;  78 723-736
• 70 Lang G E. Zentralvenenverschlüsse.  Klin Monatsbl Augenheilkd. 2007;  224 R95-R109
• 71 Kuhli C, Hattenbach L O, Scharrer I et al. High prevalence of resistance to APC in young patients with retinal vein occlusion.  Graefes Arch Clin Exp Ophthalmol. 2002;  240 163-168
• 72 Kuhli C, Scharrer I, Koch F et al. Factor XII deficiency: A thrombophilic risk factor for retinal vein occlusion.  Am J Ophthalmol. 2004;  137 459-464
• 73 Hayreh S S. Classification of central retinal vein occlusion.  Am Ac Ophthalmol. 1983;  90 458-474
• 74 Hayreh S S, Rojas P, Podhajsky P et al. Ocular neovascularization with retinal vascular occlusion-III. Incidence of ocular neovascularization with retinal vein occlusion.  Ophthalmology. 1983;  90 488-506
• 75 Quinlan P M, Elman M J, Bhatt A K et al. The natural course of central retinal vein occlusion.  Am J Ophthalmol. 1990;  110 118-123
• 76 Chen H C, Wiek J, Gupta A et al. Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion.  Br J Ophthalmol. 1998;  82 162-167
• 77 Hansen L L, Wiek J, Schade M et al. The effect and compatibility of isovolaemic haemodilution in the treatment of ischaemic and non-ischaemic central retinal vein occlusion.  Ophthalmologica. 1998;  199 90-99
• 78 Hansen L L, Wiek J, Wiederholt M. A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution.  Brit J Ophthalmol. 1989;  73 895-899
• 79 Hattenbach L O, Wellermann G, Steinkamp G W K et al. Visual outcome after treatment with low dose rt-PA or hemodilution in ischemic central retinal vein occlusion.  Ophthalmologica. 1999;  213 360-366
• 80 Opremcak E M, Rehmar A J, Ridenour C D et al. Radial optic neurotomy for CRVO: 117 consecutive cases.  Retina. 2006;  26 297-305
• 81 Hasselbach H C, Ruefer F, Feltgen N et al. Treatment of central retinal vein occlusion by radial optic neurotomy in 107 cases.  Graefes Arch Clin Exp Ophthalmol. 2007;  245 1145-1156
• 82 Weis E, Gan K D, Hinz B J et al. A retrospective cohort study of radial optic neurotomy for severe central retinal vein occlusions.  Can J Ophthalmol. 2008;  43 73-78
• 83 Feltgen N, Herrmann J, Sammain A et al. Arteriovenous dissection after isovolaemic haemodilution in branch retinal vein occlusion: a nonrandomised prospective study.  Graefes Arch Clin Exp Ophthalmol. 2006;  244 829-835
• 84 Iturralde D, Spaide R F, Meyerle C B et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study.  Retina. 2006;  26 279-284
• 85 Kreutzer T C, Alge C S, Wolf A H et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion.  Br J Ophthalmol. 2008;  92 351-355
• 86 Priglinger S G, Wolf A H, Kreutzer T C et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial.  Retina. 2007;  27 1004-1012
• 87 Stahl A, Agostini H, Hansen L L et al. Bevacizumab in retinal vein occlusion – results of a prospective case series.  Graefes Arch Clin Exp Ophthalmol. 2007;  245 1429-1436
• 88 Ferrara D C, Koizumi H, Spaide R F. Early bevacizumab treatment of central retinal vein occlusion.  Am J Ophthalmol. 2007;  144 864-871
• 89 Jonas J B, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases.  Prog Retin Eye Res. 2005;  24 587-611